InflaRx (IFRX) pops on positive INF904 Phase 2a results in HS & CSU; Q3 filing shows €44.4M liquidity and runway into 2027 — Nov 10, 2025
InflaRx reported topline Phase 2a data for oral C5aR inhibitor INF904 in hidradenitis suppurativa and chronic spontaneous urticaria, showing no serious adverse events and clinically meaningful improvements in both conditions. The company ended Q3 2025 with €44.4 million in funds and projects a cash runway into 2027. A Phase 2b HS trial is planned for 2026.
